Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 825 of 2051 entries
View as:

A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)

Phase: N/A Priority: Normal
NCT ID: NCT06630117 Org: User:
Start: 03/01/24 End: 01/25/27 Due: 01/25/28

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Phase: N/A Priority: Normal
NCT ID: NCT01485614 Org: User:
Start: 02/10/12 End: 10/09/19 Due: 10/09/20

Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)

Phase: N/A Priority: Normal
NCT ID: NCT00751413 Org: User:
Start: 08/31/08 End: 01/31/09 Due: 01/31/10

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Phase: N/A Priority: Normal
NCT ID: NCT00813995 Org: User:
Start: 12/09/08 End: 08/09/10 Due: 08/09/11

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

Phase: N/A Priority: Normal
NCT ID: NCT02203149 Org: User:
Start: 08/01/14 End: 05/16/16 Due: 05/16/17

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Phase: N/A Priority: Normal
NCT ID: NCT02563002 Org: User:
Start: 11/30/15 End: 07/17/23 Due: 07/17/24

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Phase: N/A Priority: Normal
NCT ID: NCT03745989 Org: User:
Start: 02/22/19 End: 03/19/21 Due: 03/19/22

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)

Phase: N/A Priority: Normal
NCT ID: NCT01554189 Org: User:
Start: 04/30/12 End: 04/30/13 Due: 04/30/14

Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)

Phase: N/A Priority: Normal
NCT ID: NCT00076856 Org: User:
Start: 03/31/04 End: 03/31/06 Due: 03/31/07

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Phase: N/A Priority: Normal
NCT ID: NCT01302691 Org: User:
Start: 01/01/11 End: 04/01/12 Due: 04/01/13

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00441012 Org: User:
Start: 12/31/06 End: 06/30/08 Due: 06/30/09

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase: N/A Priority: Normal
NCT ID: NCT04195750 Org: User:
Start: 02/27/20 End: 09/17/26 Due: 09/17/27

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Phase: N/A Priority: Normal
NCT ID: NCT01512693 Org: User:
Start: 02/23/12 End: 04/24/12 Due: 04/24/13

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Phase: N/A Priority: Normal
NCT ID: NCT02410590 Org: User:
Start: 07/31/15 End: 10/31/16 Due: 10/31/17

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Phase: N/A Priority: Normal
NCT ID: NCT00111891 Org: User:
Start: 06/30/05 End: 08/31/05 Due: 08/31/06

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Phase: N/A Priority: Normal
NCT ID: NCT02579863 Org: User:
Start: 10/19/15 End: 07/13/20 Due: 07/13/21

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Phase: N/A Priority: Normal
NCT ID: NCT00654420 Org: User:
Start: 03/19/08 End: 02/13/12 Due: 02/13/13

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Phase: N/A Priority: Normal
NCT ID: NCT01537120 Org: User:
Start: 12/31/11 End: 10/31/12 Due: 10/31/13

A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

Phase: N/A Priority: Normal
NCT ID: NCT01537900 Org: User:
Start: 10/01/13 End: 07/31/14 Due: 07/31/15

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Phase: N/A Priority: Normal
NCT ID: NCT03921424 Org: User:
Start: 11/05/19 End: 05/03/21 Due: 05/03/22

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

Phase: N/A Priority: Normal
NCT ID: NCT00243568 Org: User:
Start: 09/01/05 End: - Due: -

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00157950 Org: User:
Start: 10/31/05 End: 06/30/06 Due: 06/30/07

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Phase: N/A Priority: Normal
NCT ID: NCT03221634 Org: User:
Start: 08/01/17 End: 06/10/21 Due: 06/10/22

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

Phase: N/A Priority: Normal
NCT ID: NCT00907517 Org: User:
Start: 07/29/09 End: 06/13/11 Due: 06/13/12

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Phase: N/A Priority: Normal
NCT ID: NCT00482417 Org: User:
Start: 12/31/02 End: 05/31/03 Due: 05/31/04